Biotech Values

[ghmm]

$NKTR in the quarterly Call/PR said after meeting with FDA they plan to file with current data package for approval. Didn't catch exactly what but something will be a review issue (they only had 1 P3 instead of traditional 2) but said agency was open to consider as schedule 2 or better. Howard Robin and others met with White House too. So this may be getting higher ups involved at the time of heightened emphasis on Opioids. This is a pretty big news item IMO.

Additionally more info on NKTR-214 on analyst event saturday 6:15pm ET
https://edge.media-server.com/m6/p/cn2rdud9